Lintaz 4.5 Infusion

Piperacillin + Tazobactam
"4g, 0.5g"
AUROBINDO PHARMA LIMITED
Pack size 1 Glass Vial
Dispensing mode POM
Source INDIA
AgentAL ITTIHAD DRUG STORE
Retail Price 41.00 AED

Indications

Lintaz 4.5 Infusion is used for: Septicaemia, Nosocomial pneumonia

Adult Dose

Intravenous Nosocomial pneumonia Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min. When used empirically, combination w/ aminoglycoside or antipseudomonal fluoroquinolone is recommended. Empiric therapy for febrile neutropenic patients Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min. Complicated intra-abdominal infections Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min. Complicated urinary tract infections; Skin and soft tissue infections Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min.

Child Dose

Intravenous Child: Usually <40 kg: 240–300 mg PIP/kg/day 8 hourly Alternatively Nosocomial pneumonia Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose; >12 yr Same as adult dose. Empiric therapy for febrile neutropenic patients Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose; >12 yr Same as adult dose. Complicated intra-abdominal infections Child: 2-12 yr 112.5 mg/kg (piperacillin 100 mg and tazobactam 12.5 mg) 8 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose.

Renal Dose

Renal impairment: Haemodialysis patients: 2.25 g 12 hrly; additional dose of 0.75 g after each dialysis session. CAPD: 2.25 g 12 hrly. CrCl (ml/min) Dosage Recommendation <20 2.25 g 8 hrly. 20-40 2.25 g 6 hrly.

Administration

Reconstitution Reconstitute initially (2.25 g in 10 mL, 4.5 g in 20 mL) w/ water for inj, glucose 5% or NaCl 0.9%, then further dilute to 50-150 mL w/ compatible infusion soln. IV Administration Infusion over 30 min

Contra Indications

Hypersensitivity.

Precautions

Pregnancy and lactation, pseudomembranous colitis. Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients with low K reserves. Increased risk of fever and rash in patients with cystic fibrosis. Increased risk of bleeding manifestations. Prolonged treatment may increase risk of superinfections. Convulsions or neuromuscular excitability may occur when high doses are used, especially in renally impaired patients. Renal impairment. Lactation: Low concentrations of piperacillin excreted in breast milk; tazobactam unknown; use caution

Pregnancy-Lactation

Pregnancy Piperacillin and tazobactam cross placenta in humans; however, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage Animal data No fetal structural abnormalities observed in rats or mice when drug administered intravenously during organogenesis at doses 1 to 2 times and 2 to 3 times human dose of piperacillin and tazobactam, respectively; based on body-surface area (mg/m2); however, fetotoxicity in presence of maternal toxicity was observed in developmental toxicity and peri/postnatal studies conducted in rats (intraperitoneal administration prior to mating and throughout gestation or from gestation day 17 through lactation day 21) at doses < maximum recommended human daily dose based on body-surface area (mg/ m²) Lactation Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been Studied; no information available on effects of piperacillin and tazobactam on breastfed child or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for drug and any potential adverse effects on breastfed child from therapy or from underlying maternal condition

Interactions

Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.

Adverse Effects

Side effects of Piperacillin + Tazobactam : >10% Diarrhea (7-11%) 1-10% Constipation (1-8%), Headache (1-8%), Insomnia (4-7%), Nausea (2-7%), Fever (2-5%), Oral candidiasis (2-4%), Rash (2-4%), Vomiting (2-4%), Dyspepsia (3%), Pruritus (3%), Pain (2-3%), Hypertension (2%), Leukopenia (1%), Thrombocytopenia (1.4%) <1% Anaphylaxis, Agranulocytosis, Thrombocytopenia, Eosinophilia, Leukopenia, Positive Coombs test, Prolonged PT and PTT, Transient LFT and creatinine elevations.Seizure, Pulmonary edema, Pulmonary embolism

Mechanism of Action

Piperacillin has an antimicrobial activity against a wide range of gm-ve organisms including K. pneumoniae, P. aeruginosa, Enterobacteriaceae and against gm+ve organisms eg E. faecalis and B. fragilis. Tazobactam is a penicillanic acid sulfone derivative with beta-lactamase inhibitory properties. In combination, tazobactam enhances the activity of piperacillin against beta-lactamase-producing bacteria.

Note

Lintaz 4.5 "4g, 0.5g" Infusion manufactured by AUROBINDO PHARMA LIMITED. Its generic name is Piperacillin + Tazobactam. Lintaz 4.5 is availble in United Arab Emirates. Farmaco UAE drug index information on Lintaz 4.5 Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Piperacillin + Tazobactam :

Infusion
Yanoven "2g, 0.25g"
ARWAN PHARMACEUTICAL INDUSTRIES LEBANON s.a.l.
Infusion
Yanoven "4g, 0.5g"
ARWAN PHARMACEUTICAL INDUSTRIES LEBANON s.a.l.
Infusion
Tazocin 4.5g "4g, 0.5g"
WYETH LEDERLE S.p.A.
Infusion
Tazocin 2.25g "2g, 0.25g"
WYETH LEDERLE S.p.A.
Infusion
Tactam 4g/0.5g
Julphar (Gulf Pharmaceutical Industries)